Rasburicase
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Rasburicase: From Hyperuricemia to Renal Hypouricemia
One-Sentence Summary
Rasburicase is a recombinant urate oxidase originally used to lower uric acid in hyperuricemia. The TxGNN model predicts it may be effective for renal hypouricemia, but no clinical trials and no publications support this prediction. The mechanism also points the wrong way: the condition already involves low uric acid, so this prediction is most likely a model artifact.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyperuricemia (approved indication text is not listed in the Singapore registration) |
| Predicted New Indication | Hypouricemia, renal |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, rasburicase is a recombinant urate oxidase. It converts uric acid to allantoin and lowers serum urate, which is why it is used for hyperuricemia.
Renal hypouricemia is a condition in which serum urate is already low, for example from loss-of-function variants in URAT1 (SLC22A12) or GLUT9 (SLC2A9). Lowering urate further would be mechanistically counterproductive and could raise risk, for example exercise-induced acute kidney injury. The high TxGNN score appears to reflect proximity in the uric acid pathway of the knowledge graph rather than a plausible therapeutic link.
Other top-ranked predictions are also weak. Several hepatic and portal conditions share an identical score, which suggests a non-specific graph artifact. The one biologically plausible candidate is partial HPRT deficiency, where purine overproduction causes hyperuricemia. Even there, rasburicase is an injectable biologic with a short course and immunogenicity that limits repeat use, so it is unsuitable for chronic management. Allopurinol and febuxostat are already standard care.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12055P | FASTURTEC Powder for Solution for Infusion 1.5 mg/vial | Injection, powder, for solution | Not stated in the registration data |
Safety Considerations
- Drug Interactions: 13 interactions were identified. Two are rated Major:
- Prilocaine (Major)
- Nitrous acid (Major)
- The other 11 are rated Moderate. They mainly involve local anaesthetics (tetracaine, lidocaine, benzocaine, cocaine, proparacaine, oxybuprocaine, cinchocaine) in topical, ophthalmic or nasal forms, plus idelalisib.
- Screening point: G6PD deficiency, hemolysis and methemoglobinemia are safety concerns that would need screening before any use.
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model score alone (L5). Renal hypouricemia is already a low-urate state, so further urate lowering is mechanistically counterproductive and potentially harmful. No trials or publications support it.
To proceed, the following is needed:
- A mechanistic justification that explains why lowering urate would benefit renal hypouricemia (none is currently apparent)
- Mechanism of action data for rasburicase from DrugBank
- Package insert warnings and contraindications from the HSA
- If a more plausible indication (such as acute severe hyperuricemia in partial HPRT deficiency) is pursued, a comparison against standard therapy and a G6PD screening plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.